Anaphylaxis is a life-threatening systemic reaction, normally occurring within one to two hours of exposure to an allergen. The incidence of anaphylaxis in the United States is 2.1 per 1,000 person-years. Most anaphylactic reactions occur outside the hospital setting. Urticaria, difficulty breathing, and mucosal swelling are the most common symptoms of anaphylaxis. The most common triggers are medications, stinging insect venoms, and foods; however, unidentified triggers occur in up to one-fifth of cases. Coexisting asthma, mast cell disorders, older age, underlying cardiovascular disease, peanut and tree nut allergy, and drug-induced reactions are associated with severe or fatal anaphylactic reactions. Clinicians can obtain serum tryptase levels, reflecting mast cell degranulation, when the clinical diagnosis of anaphylaxis is not clear. Acute management of anaphylaxis involves removal of the trigger; early administration of intramuscular epinephrine; supportive care for the patient's airway, breathing, and circulation; and a period of observation for potential biphasic reactions. Only after epinephrine administration should adjunct medications be considered; these include histamine H1 and H2 antagonists, corticosteroids, beta2 agonists, and glucagon. Patients should be monitored for a biphasic reaction (i.e., recurrence of anaphylaxis without reexposure to the allergen) for four to 12 hours, depending on risk factors for severe anaphylaxis. Following an anaphylactic reaction, management should focus on developing an emergency action plan, referral to an allergist, and patient education on avoidance of triggers and appropriate use of an epinephrine auto-injector.
Anaphylaxis is a severe allergic reaction that occurs quickly and can be fatal. The incidence of anaphylaxis in the United States between 2004 and 2016 was 2.1 per 1,000 person-years, with one-fourth of anaphylactic reactions affecting children younger than 17 years.1 Most anaphylactic reactions occur outside the hospital setting (Table 1),2,3 and most individuals go to the hospital or emergency department for treatment.2,4 In the United States, the incidence of anaphylaxis peaks in children two to 12 years of age and in adults between 50 and 69 years of age.1 One out of 20 of all anaphylaxis cases may require hospitalization1,2; in the United States, hospitalizations for anaphylaxis have steadily increased over the past 10 years.5 The annual number of confirmed anaphylaxis-related deaths in the United States ranges from 186 to 225.5 The average fatality rate is 0.3% for most hospitalizations or emergency department presentations for anaphylaxis.5 Risk factors for severe or fatal anaphylaxis include coexisting asthma, mast cell disorders, age older than 50 years, underlying cardiovascular disease, peanut and tree nut allergy, and drug-induced reactions.6–10
WHAT'S NEW ON THIS TOPIC
One out of 20 of all anaphylaxis cases requires hospitalization; in the United States, hospitalizations for anaphylaxis have steadily increased over the past 10 years.
Gastrointestinal and respiratory symptoms of anaphylaxis are more likely to be overlooked in children. Only 55% of health care professionals recognize anaphylaxis without cutaneous involvement.
One-half of patients presenting to the emergency department who meet the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network diagnostic criteria for anaphylaxis receive treatment with epinephrine.
SORT: KEY RECOMMENDATIONS FOR PRACTICE
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.
BEST PRACTICES IN ALLERGY
| Recommendation | Sponsoring organization |
|---|---|
| Do not rely on antihistamines as first-line treatment in severe allergic reactions. | American Academy of Allergy, Asthma, and Immunology |
Source: For more information on the Choosing Wisely Campaign, see https://www.choosingwisely.org. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see https://www.aafp.org/afp/recommendations/search.htm.
TABLE 1. Most Common Places Anaphylactic Reactions Occur
Pathophysiology
There are two types of anaphylactic reactions: immunoglobulin E (IgE) mediated and nonimmune (i.e., direct activation).11 Most cases of anaphylaxis are IgE mediated in which antibodies to a particular allergen activate mast cells and basophils, resulting in degranulation and release of a wide variety of chemical mediators. Nonimmune anaphylaxis occurs by direct activation of mast cell and basophil receptors or complement-mediated activation. Distinction between the two types is not clinically possible, and treatment is the same for both.11
Diagnosis
Clinicians should be familiar with the differential diagnosis of anaphylaxis because many other conditions can present with signs or symptoms of anaphylaxis (Table 211,12 ). Signs and symptoms of an allergic reaction typically occur within one to two hours of exposure to an allergen, usually within 30 minutes for a food allergy and faster for parenteral medication or insect stings. Most acute allergic reactions are mild and self-limited, involving a single organ system, often the skin, with symptoms such as swelling of the lips or face, hives or welts, or tingling of the mouth. Anaphylaxis is distinguished from a mild or moderate allergic reaction by the sudden involvement of two or more organ systems manifesting with a variety of symptoms such as difficulty breathing, swelling of the tongue, swelling or tightness in the throat, wheezing, sudden persistent cough, abdominal pain, vomiting, and hypotension13 (Table 314 ). Anaphylaxis can also be diagnosed by the isolated involvement of the cardiovascular system in the setting of hypotension or cardiovascular collapse after exposure to a known allergen.14 Although isolated hypotension is a rare presentation of anaphylaxis, it often results in hospitalization and can be a marker of severity.15
TABLE 2. Differential Diagnosis of Anaphylaxis
| Presentation | Differential diagnosis |
|---|---|
| Flush syndrome | Autonomic epilepsy Carcinoid Medullary carcinoma of the thyroid Perimenopausal hot flashes Red man syndrome (i.e., adverse reaction to vancomycin) |
| Hypotension | Cardiogenic shock Hypovolemic shock Septic shock Vasovagal reaction |
| Miscellaneous | Anxiety, panic attacks Hereditary angioedema Leukemia with excess histamine production Systemic mastocytosis |
| Postprandial collapse | Airway foreign body Monosodium glutamate ingestion Scombroid fish poisoning Sulfite ingestion |
| Respiratory distress with wheezing or stridor | Aspiration of a foreign body Asthma and chronic obstructive pulmonary disease exacerbation Vocal cord dysfunction syndrome |
Adapted with permission from Tang AW. A practical guide to anaphylaxis [published correction appears in Am Fam Physician. 2004; 69(5):1049]. Am Fam Physician. 2003;68(7):1328, with additional information from reference 11.
TABLE 3. Diagnostic Criteria for Anaphylaxis
| Anaphylaxis is highly likely when any one of the following three sets of criteria is met: |
| Acute onset of an illness (i.e., minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives; pruritus or flushing; swollen lips, tongue, or uvula; and at least one of the following: |
| Respiratory compromise (e.g., dyspnea, wheezing, bronchospasm, stridor, reduced peak expiratory flow, hypoxemia) |
| Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse], syncope, incontinence) |
| Two or more of the following that occur rapidly (i.e., minutes to several hours) after exposure to a likely allergen for that patient: |
| Involvement of the skin, mucosal tissue, or both (e.g., generalized hives; pruritus or flushing; swollen lips, tongue, or uvula) |
| Respiratory compromise (e.g., dyspnea, wheezing, bronchospasm, stridor, reduced peak expiratory flow, hypoxemia) |
| Reduced blood pressure or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence) |
| Persistent gastrointestinal symptoms (e.g., abdominal cramps, vomiting) |
| Reduced blood pressure that occurs rapidly (i.e., minutes to several hours) after exposure to a known allergen for that patient |
| Infants and children: low systolic blood pressure (age-specific)* or a 30% or greater decrease in systolic blood pressure |
| Adults: systolic blood pressure of less than 90 mm Hg or a 30% or greater decrease from baseline |
*—Defined as less than 70 mm Hg in children one month to one year of age; less than 70 mm Hg + (2 × the child's age) in those one to 10 years of age; and less than 90 mm Hg in those 11 to 17 years of age.
Adapted with permission from Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):393.
Making an accurate diagnosis is important because epinephrine is administered more often to patients diagnosed with anaphylaxis.16,17 Clinicians must be familiar with and recognize the wide spectrum of presentations to avoid a missed diagnosis (Table 42,4,16,18–22 ). For example, syncope and hypotension are more common presentations in drug-induced anaphylaxis,7 and in children, gastrointestinal and respiratory symptoms are more likely to be overlooked despite the more common occurrence of gastrointestinal symptoms.18,23 In one study, only 55% of health care professionals recognized anaphylaxis without cutaneous involvement.24
TABLE 4. Most Common Signs and Symptoms of Anaphylaxis by Age Group
| Signs and symptoms | All ages | Children and adolescents zero to 18 years of age |
|---|---|---|
| Mucocutaneous | 73% to 98% | 78% to 97% |
| Throat tightness | 36% | 11% |
| Urticaria | 30% to 58% | 90% |
| Angioedema | 23% to 53% | – |
| Pruritus | 15% to 49% | – |
| Flushing | 14% to 33% | – |
| Tongue swelling | 8% | 13.5% |
| Throat tingling | – | 10% |
| Respiratory | 74% to 81% | 81% to 88% |
| Increased/difficulty breathing or dyspnea | 63% to 66% | 88% |
| Laryngeal edema | 45% | – |
| Wheezing | 15% to 24% | 35% |
| Coughing | 4% to 11% | 26% |
| Stridor | 1% to 4% | 21% |
| Shortness of breath | – | 23% |
| Cardiovascular | 31% to 39% | 9% to 13% |
| Chest pain | 8% to 16% | – |
| Hypotension | 8% to 12% | – |
| Dizziness, fainting or loss of consciousness | 5% to 16% | – |
| Pale, floppy, cyanotic, or loss of consciousness | – | 12% |
| Gastrointestinal | 17% to 33% | 27% |
| Abdominal pain | 9% | 7% |
| Nausea or vomiting | 7% to 23% | 24% |
| Abdominal cramping | 5% | – |
| Diarrhea | 3% to 5% | – |
LABORATORY TESTING
Serum tryptase levels reflect mast cell degranulation and peak one to one and a half hours after the onset of anaphylaxis. Their testing availability limits the feasibility of measuring serum tryptase in an acute setting, and the treatment of a patient with possible anaphylaxis should not be based on serum tryptase levels alone.25 If a diagnosis of anaphylaxis is in doubt, results of laboratory testing up to three hours after symptom onset can support the diagnosis in some patients26; however, levels are often normal in food-triggered reactions.10,11
Triggers
The most common causes of anaphylaxis are foods, medications, and stinging insect venom. However, there are a wide range of specific triggers (Table 52,4,6,7,18,27–29 ), and the frequency varies with age and geographic region.18–20,27 In the United States, food-triggered anaphylaxis is most common in children from birth to four years of age, whereas anaphylaxis to medications is more common in adults 50 years and older.21,30,31
TABLE 5. Common Triggers for Anaphylaxis
| Allergen | Percentage of all patients who experience anaphylaxis* |
|---|---|
| Medications: Antibiotics (most commonly beta-lactams [4%]), nonsteroidal anti-inflammatory drugs (7% to 12%), chemotherapy agents (2%), allopurinol, angiotensin-converting enzyme inhibitors, aspirin, biologic modifiers (e.g., interferon), opioids | 21% to 58.8% |
| Foods: Eggs (1% to 4%), fish/shellfish (10% to 15%), milk (2% to 10%, highest in infants), peanuts (2% to 13%), tree nuts (7% to 12%) | 32% to 37% |
| Insect venom: Hymenoptera stinging insects (e.g., bees, wasps, fire ants) | 15.2% to 25% |
| Idiopathic anaphylaxis | 11% to 19.5% |
| Occupational allergens: Food allergens, medications, bee stings, tick bites, natural rubber latex (2.6% to 6.2%), and chemicals (e.g., dyes, bleaches, insecticides, fungicides, iodine, chlorhexidine) | – |
| Physical factors (rare): Cold, heat, exercise (2%), sunlight | – |
| Radiocontrast media | 1% to 5% |
*—Percentages for subcategories are for overall triggers of the related study sample population.
Clinicians and patients do not always correctly identify the causative agent.16 Referral of patients with an anaphylactic reaction for allergy testing may help determine the offending trigger. Idiopathic triggers occur in up to 20% of anaphylactic cases, and identifying the trigger of an anaphylactic episode is not always possible.5,9,18,32
Management of Anaphylaxis
EPINEPHRINE
The mainstay of treatment of acute IgE-mediated or nonimmune anaphylaxis is epinephrine (Figure 18,10,11,13,21,26,33–36 ). Epinephrine causes an increase in peripheral vascular resistance plus inotropic and chronotropic cardiac effects, leading to an increase in blood pressure. It causes bronchodilation and decreased mucosal edema through the vasodilation of the skeletal and smooth muscles in the airways and stabilization of mast cells and basophils.
FIGURE 1.
Algorithm for the management of anaphylaxis in the outpatient setting.
The onset of action of epinephrine is usually three to five minutes, and intramuscular administration into the anterolateral thigh is the preferred route.8,10,25,26,33,34 Epinephrine auto-injectors can be used in health care settings and are advantageous because they are quicker to administer and decrease dosing errors.26 At recommended doses, the most common adverse effects of epinephrine include agitation, anxiety, tremulousness, headache, dizziness, pallor, and palpitations. There are no absolute contraindications to administering epinephrine for anaphylaxis.
Delayed or lack of epinephrine use continues to be a problem despite current guidelines emphasizing the importance of early administration.37 Retrospective studies show that approximately one-half of patients presenting to the emergency department who meet the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network diagnostic criteria for anaphylaxis receive treatment with epinephrine.16,32,38 An initial injection of epinephrine before the patient arrives at the emergency department decreases the likelihood of hospital admission,39 and not administering epinephrine to treat anaphylaxis is associated with worse outcomes and mortality.33,34 Reasons for failure to use epinephrine include delayed presentation,40 misdiagnosis as a mild or moderate allergic reaction,16,19,32 and failure to use the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network diagnostic criteria.15,41 Clinicians cannot predict whether an allergic reaction episode will rapidly progress; therefore, early use of epinephrine should be considered even with mild symptoms or single-system involvement.8
HISTAMINE H1 AND H2 ANTAGONISTS AND CORTICOSTEROIDS
Antihistamines and corticosteroids are not effective first-line treatments for anaphylaxis. Guidelines recommend that antihistamines and corticosteroids be used only as an adjunct to epinephrine.8,11,25 Antihistamines have an onset of action of one to two hours. Although they improve cutaneous erythema and decrease pruritus, they have not been shown to reverse upper airway obstruction or improve hypotension.42 The onset of action for corticosteroids is approximately six hours; therefore, they have little to no effect on initial signs and symptoms of anaphylaxis. A systematic review of corticosteroid use in the management of anaphylaxis was inconclusive for the reduction of biphasic reactions; however, corticosteroids may decrease the length of hospital stay.43
BETA2 AGONISTS AND GLUCAGON
Beta2 agonists are used for the treatment of patients with reactive airways disease or any patient presenting with signs of active bronchospasm.8,25 Any patient with refractory hypotension, especially those being treated with beta blockers, should be given glucagon because it has inotropic and chronotropic effects that are not mediated through beta receptors.8,13,25
INTRAVENOUS FLUIDS AND OXYGEN THERAPY
Oxygen should be administered to patients presenting with respiratory symptoms, decreased oxygen saturation, or hypotension.8 During anaphylaxis, vascular dilation and increased permeability can lead to intravascular fluid shifting into the extravascular space, resulting in distributive shock. Therefore, it is essential to establish two large-bore intravenous access sites and administer fluids when signs or symptoms of shock occur (Figure 18,10,11,13,21,26,33–36 ). Placing a patient with hypotension in a recumbent position with the lower extremities raised is preferred to elevating the head, even if the patient has an upper airway obstruction.8,35
TRANSFER TO HIGHER LEVEL OF CARE
Patients should be transported to the hospital for continued therapy and monitoring, especially those with an initial presentation of significant respiratory or circulator y compromise, and patients with refractory anaphylaxis. Refractory anaphylaxis occurs in patients who do not respond to initial treatment with epinephrine, supplemental oxygen, intravenous fluid resuscitation, and second-line medications.
Observation Period
Biphasic reactions occur in less than 5% of patients diagnosed with anaphylaxis2,44 and are defined as the recurrence of anaphylaxis within 72 hours of the initial reaction without reexposure to the allergen. A recent meta-analysis showed that an observation time greater than six hours after resolution of anaphylactic symptoms could exclude the recurrence of a secondary reaction in more than 95% of patients.45 A minimum observation period of four hours supports current guidelines, with longer observation periods recommended based on individualized factors such as previous biphasic reaction, severity of initial presentation, treatment with multiple doses of epinephrine, a previously protracted anaphylactic reaction, unknown anaphylactic trigger, or presence of risk factors for severe or fatal anaphylaxis.8,11,25,44,46
Post-Anaphylaxis Care
ANAPHYLAXIS ACTION PLAN
All patients at risk of anaphylaxis should be provided with an action plan instructing them on how to manage an episode of anaphylaxis, including the proper administration of epinephrine.8,11,25,47 Parents of at-risk children, especially children with a documented food allergy who attend school, preschool, or childcare, should share the action plan with the staff caring for their children.47 The action plan should include documentation of confirmed allergens, signs and symptoms of anaphylaxis, an emphasis on epinephrine as the first-line treatment, the first aid response, identification of the child including a photo, and parent or guardian contact information. An example plan is available at https://www.healthychildren.org/SiteCollectionDocuments/AAP_Allergy_and_Anaphylaxis_Emergency_Plan.pdf. Preventive measures to decrease the risk of repeat episodes of anaphylaxis are listed in eTable A.
eTABLE A Preventive Measures to Decrease the Risk of Repeat Episodes of Anaphylaxis
| Patient measures |
| Maintain a current and appropriately dosed epinephrine auto-injector near where the patient spends most of his or her time; take it when traveling and keep a placebo trainer for education |
| Properly diagnose the offending allergen and implement practical strategies to decrease the risk of accidental exposure to known allergen |
| Patients with food-induced anaphylaxis: use high scrutiny when reading ingredient lists and ask what is in the food prepared for them |
| Patients with medication-induced anaphylaxis: avoid the offending medication and those with known cross reactivity; wear a medical alert bracelet to prevent administration of the offending medication |
| Patients with insect-induced anaphylaxis: avoid known locations of the offending arthropods |
| Provide age-appropriate education of children and adults with severe allergies and their peers on how to recognize and treat new symptoms if they reappear |
| Physician measures |
| Implement a waiting period of 20 to 30 minutes after the patient is given an injection of a medication or biologic agent; avoid administering injections if an alternative oral medication is available |
| Optimize management of reactive airways disease and coronary artery disease |
| Consider substituting other medications for those that may blunt the effect of epinephrine, such as beta blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor antagonists, tricyclic antidepressants, and monoamine oxidase inhibitors |
| Maintain up-to-date medical information and develop an anaphylaxis action plan |
| Train staff to recognize and manage acute allergic reactions |
| Be aware that unexpected allergic reactions can initially occur outside the home in patients not previously identified as being at high risk |
| Consider institutional supplies of epinephrine auto-injector for general use |
| Consider allergen-specific immunotherapy in cases of Hymenoptera venom–induced anaphylaxis |
Information from:
Alvarez-Perea A, Tomás-Pérez M, Martínez-Lezcano P, et al. Anaphylaxis in adolescent/adult patients treated in the emergency department: differences between initial impressions and the definitive diagnosis. J Investig Allergol Clin Immunol. 2015;25(4):288–294.
Arnold JJ, Williams PM. Anaphylaxis: recognition and management. Am Fam Physician. 2011;84(10):1111–1118.
Vale S, Smith J, Said M, et al. ASCIA guidelines for prevention of anaphylaxis in schools, pre-schools and childcare: 2015 update. J Paediatr Child Health. 2015;51(10):949–954.
EPINEPHRINE AUTO-INJECTOR PRESCRIPTION
Epinephrine auto-injectors are safe when used correctly. Guidelines recommend that all patients diagnosed with an anaphylactic reaction be prescribed an auto-injector. Patients treated in the emergency department for anaphylaxis commonly do not receive a prescription when they are discharged.48 Patients do not always fill the prescription, even when it is offered,49 or carry the epinephrine auto-injectors with them at all times.50,51 Common reasons patients do not comply with treatment include thinking that they will not be exposed to the allergen or that their symptoms are not severe enough, that they have never had to use the auto-injector before, and that they either forget or do not feel a need to carry it with them at all times.50 Auto-injectors can be expensive and often have a one-year expiration date, requiring an annual purchase of one or more. Effective patient education during examinations should emphasize the importance of keeping the auto-injector available for immediate use.
ALLERGIST REFERRAL
Referral to an allergist is appropriate if a clinician feels inadequately trained to provide education or if the patient presents after the reaction and the offending agent cannot be confirmed.8,25 Allergists should obtain a detailed patient history, coordinate additional outpatient testing, offer additional allergen avoidance counseling, and provide the patient with medical alert or identification jewelry.
This article updates previous articles on this topic by Arnold and Williams,36 and Tang.12
Data Sources: A PubMed search was completed using the key terms anaphylaxis, epinephrine, antihistamine, corticosteroids, glucagon, management, epidemiology, diagnosis, biphasic, and fatal. The search included meta-analyses, systematic reviews, practice guidelines, clinical trials, and original studies. Also searched were the Cochrane database, ECRI Guidelines Trust, Essential Evidence Plus, and the U.S. Preventive Services Task Force. Search dates: August 28, 2019, and April 29, 2020.
The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of the Navy, Department of the Air Force, Uniformed Services University of the Health Sciences, Department of Defense, or the U.S. government.
